Adeza remedies issue of non-compliance with Nasdaq

By Elaine Rigoli

Tampa, Fla., Aug. 10 - Adeza Biomedical Corp. said the Nasdaq told the company that the recent appointment of C. Gregory Vontz, an independent member of the company's board of directors, to the company's audit committee has restored the company's compliance with Nasdaq rules.

The company had previously received a letter from the Nasdaq informing the company that, due to the resignation of Nancy D. Burrus from the board of directors, Adeza was no longer in compliance with Nasdaq rules that require that the company's audit committee have at least three independent directors.

Based in Sunnyvale, Calif., Adeza is a medical technology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.